Farmavita.Net member is developing innovative concept for glogal branding and distribution of remedies and devices for therapy of arthritis.
Company is looking to joint-venture, collaborative development or in-licensing of non-prescrition products, on exclusive basis.
For more details please contact Farmavita.Net.
Farmavita.Net member has developed technology which enables development of oral dosage forms with controlled and site specific release of active pharmaceutical ingredients. Patent pending application.
Company is looking for following types of cooperation:
- Joint-venture and private equity partners
- Collaborative product development
- Consulting or contract research contracts
An Asia based international company is looking for technologies in the following field:Type of Tech Request: Licensing
The gradual spread of software automation in drug development may be getting a boost from open source systems. Most e-clinical systems today--from data capture and storage to trial management and operations--are proprietary, despite the excellent work that solutions providers have done to make their products compatible with existing standards-based and de facto standard industry systems.
Our present communication deals with physicochemical parameters, preliminary phytochemical studies and pharmacological impact of Murdannia nudiflora (L) Brenan as analgesic plant which is used in folklore uses of Assam. No reports are available on standardization parameters hence, the present attempt was undertaken to investigate the standardization parameters to establish its authenticity. The study revealed the presence of wide range of phytoconstituents. The determination of these characters will aid future investigators in their Pharmacological analysis of this species.
February 26-27, 2015 in Berlin,Germany
This meeting is an ideal chance to benchmark with other market leaders in this field who are utilising the unique MSL function to help regain the credibility of the pharmaceutical industry, as a value-adding stakeholder and partner to the healthcare ecosystem.
Seven targeted therapies are available for the treatment of RCC but there is still considerable pipeline activity. Currently approved targeted therapies have been unable to produce durable responses in RCC patients and only delay progression. As a consequence, effective treatment options capable of sustaining responses in RCC are still required.
Complete your profile
The more information you put into your profile the easier it is for others to find you. Compare your profile with those of other members. The more you put into the network, the more benefit you will derive from community.